SUGEN

SUGEN is a biopharmaceutical company focused on the discovery and development of small molecule drugs which target specific cellular signal transduction pathways. These signalling pathways are regulated by cell-surface receptors or intracellular signalling molecules known as tyrosine kinases ("TKs"), tyrosine phosphatases ("TPs") and serine-threonine kinases ("STKs"), three of the largest known families of receptors in the body and key regulators of critical cellular functions. Aberrant signalling of TKs, TPs and STKs has been shown to result in a variety of chronic and acute pathological diseases, including cancer and diabetes as well as in dermatologic, ophthalmic, neurologic and immune disorders. The Company believes that compounds designed to target certain kinases and phosphatases and inhibit enzyme activity or prevent the binding of downstream signalling molecules make attractive therapeutic product candidates.

Contact Details: 230 E. Grand Ave South San Francisco CA 94080 United States of America Tel: 650 553 8741 Fax: 650 553 8348 Email: WWW: www.sugen.com/

Loading...

Recent Publications by SUGEN:
Effect of Terminalia arjuna extract on adriamycin-induced DNA damage. The effect of a bark extract of Terminalia arjuna (TAE) was studied on the...	19th December, 2008	Division of Cancer Biology, Sugen Life Sciences, Tirupati, 517505, AP,	Phytother Res. 2008 Sep;22(9):1188-94. DOI Direct Link
High-performance liquid chromatographic method for determination of reversible isomers of SU5416. SU5416 shows light-induced reversible geometric isomerism. A simple,...	29th June, 2006	Formulations Research, SUGEN Inc., 230 S. Grand Avenue, South San	J Chromatogr A. 2006 Mar 31;1110(1-2):73-80. Epub 2006 Feb 10. DOI Direct Link
Simultaneous determination of Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) and its interconvertible geometric isomer (SU5886) in rat plasma by LC/MS/MS. Z-3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) is a...	23rd May, 2006	Department of Bioanalysis and Phamarcokinetcs, Sugen, 230 E. Grand Ave.,	J Pharm Biomed Anal. 2005 Jul 1;38(3):479-86. Epub 2005 Mar 2. DOI Direct Link
PAK4 mediates morphological changes through the regulation of GEF-H1. Precise spatial and temporal regulation of Rho GTPases is required in...	20th September, 2005	SUGEN Incorporated, 230 East Grand Avenue, South San Francisco, CA 94080,	J Cell Sci. 2005 May 1;118(Pt 9):1861-72. Epub 2005 Apr 12. DOI Direct Link
Transcriptional-based screens for pathway-specific, high-throughput target discovery in endothelial cells. With the sequence of the human genome at hand, target discovery strategies...	13th May, 2005	SUGEN, Inc.,	J Biomol Screen. 2004 Dec;9(8):704-11. DOI Direct Link
→View more SUGEN research publications.

Press Releases on SUGEN:
Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market	29th June, 2009	Mylan Inc.	PITTSBURGH, June 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has executed a definitive agreement with Biocon Limited, a publicly traded company on the Indian stock
Longitude Capital Closes $325 Million Life Sciences Fund	8th July, 2008	Longitude Capital	MENLO PARK, Calif., July 8 /PRNewswire/ -- Longitude Capital today announced the closing of its first investment vehicle, Longitude Venture Partners, L.P. (the "Fund"), a $325

BioNews Results for SUGEN:
OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer	NewsBlaze:  Jun 17 2009 7:27AM Matching: sugen
OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer	RBC Dain Raushcer:  Jun 17 2009 6:47AM Matching: sugen
SAP and SAP User Group Executive Network (SUGEN) Announce SAP(R) Enterprise Support Milestones	Stockwatch:  Apr 29 2009 5:38AM Matching: sugen
SAP and SAP User Group Executive Network (SUGEN) Announce SAP(R) Enterprise Support Milestones	PR Newswire:  Apr 29 2009 5:38AM Matching: sugen
SAP and SAP User Group Executive Network (SUGEN) Announce SAP(R) Enterprise Support Milestones	PR Newswire via Yahoo!:  Apr 29 2009 5:35AM Matching: sugen
Promote your company here: BioNewsCast - Press Release Distribution	→View more SUGEN news.

SUGEN Patents:
US Patent No.	Title
6696463	3-heteroarylidenyl-2-azaindolinones active as protein tyrosine kinase inhibitors
6855730	3-methylidenyl-2-indolinone modulators of protein kinase
6861418	4-aryl substituted indolinones
6861442	PYK2 and inflammation
6878733	Formulations for pharmaceutical agents ionizable as free acids or free bases
→View more SUGEN patents.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 29 individuals from SUGEN using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 458 times since April 2007, the link to the organisation's website has been followed 78 times

Recent Search Terms used to find this page: SUGEN Inc logo San Fran | sugen | PAK4 Sugen | longitude capital logo | sugen | Sugen.COM | SUGEN | www.sugen.com | sugenlife.com | t | .

Search for more companies in South San Francisco

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for SUGEN